financetom
Business
financetom
/
Business
/
Cadence to buy BETA CAE Systems for $1.24 billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cadence to buy BETA CAE Systems for $1.24 billion
Mar 5, 2024 7:29 AM

March 5 (Reuters) - Cadence Design Systems ( CDNS ) will

buy BETA CAE Systems International AG, which makes software for

analyzing car and jet engine designs, for $1.24 billion in cash

and stock, Cadence said on Tuesday.

Cadence will pay about $744 million in cash and the rest in

stock. The San Jose, California-based company said it will take

on debt to pay for the deal but pay the debt down with cash

generated from operations.

Cadence's shares were down 1.5% premarket, showing little

reaction to the news.

Cadence is one of the largest makers of software used in

designing computer chips, helping chipmakers decide where to

place billions of transistors to form complex circuits. But over

the past six years, it has been moving into design software for

the larger physical systems from circuit boards to airplanes.

Last month, the company announced a supercomputer designed to

help simulate how air flows around jet engines, among other

uses.

The BETA CAE deal continues that trend. Its software is

widely used to analyze designs in automotive and aerospace

industries, with customers such as Honda Motor Co ( HMC ),

General Motors ( GM ) and Lockheed Martin ( LMT ).

The Cadence deal announced Tuesday comes after the firm's

largest rival, Synopsys, said it will spend $35 billion to buy

Ansys, another maker of physical analysis software.

The BETA CAE deal is expected to close in the second quarter

of the year and Cadence expects BETA CAE to contribute about $40

million to its 2024 revenue, Cadence said in a statement.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private
BRIEF-Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private
Jun 17, 2024
June 17 (Reuters) - Vapotherm Inc ( VAPO ): * VAPOTHERM ENTERS INTO DEFINITIVE MERGER AGREEMENT; TRANSACTION WOULD RESULT IN COMPANY GOING PRIVATE * VAPOTHERM ( VAPO ): CO'S STOCKHOLDERS TO GET $2.18 IN CASH FOR EACH OUTSTANDING SHARE OF CO COMMON STOCK HELD IMMEDIATELY PRIOR TO EFFECTIVE TIME OF MERGER Source text for Eikon: Further company coverage: ...
BRIEF-The Aaron's Company Enters into Definitive Agreement to Be Acquired by IQVentures for $10.10 Per Share
BRIEF-The Aaron's Company Enters into Definitive Agreement to Be Acquired by IQVentures for $10.10 Per Share
Jun 17, 2024
June 17 (Reuters) - Aaron's Company Inc: * THE AARON'S COMPANY ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY IQVENTURES FOR $10.10 PER SHARE * AARON'S COMPANY INC - PROPOSED DEAL FOR ENTERPRISE VALUE OF APPROXIMATELY $504 MILLION * AARON'S COMPANY INC - TRANSACTION WAS UNANIMOUSLY APPROVED BY BOARD OF DIRECTORS OF AARON'S COMPANY * AARON'S COMPANY INC - UPON...
Walt Disney's Deadpool & Wolverine to Debut in China
Walt Disney's Deadpool & Wolverine to Debut in China
Jun 17, 2024
07:15 AM EDT, 06/17/2024 (MT Newswires) -- Walt Disney's ( DIS ) Deadpool & Wolverine will hit Chinese theaters next month, the company said via a post on Weibo on Sunday. The third installment starring Ryan Reynolds and Hugh Jackman will be released on July 26, the post said. Price: 100.33, Change: +0.36, Percent Change: +0.36 ...
AstraZeneca Says FDA Approves Imfinzi to Treat Endometrial Cancer
AstraZeneca Says FDA Approves Imfinzi to Treat Endometrial Cancer
Jun 17, 2024
07:20 AM EDT, 06/17/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that the US Food and Drug Administration has approved Imfinzi combined with chemotherapy followed by Imfinzi monotherapy to treat adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient. The company said the approval was based on phase 3 data showing the therapy cut...
Copyright 2023-2026 - www.financetom.com All Rights Reserved